Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
PURPOSE OF REVIEW: Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare, aggressive malignancy that can arise from any organ and frequently presents with distant metastases. Advanced disease has a poor prognosis with median overall survival (OS) rarely exceeding 1 year even with systemic therapy. The management paradigm of advanced/metastatic EP-NEC has been extrapolated from small cell lung cancer (SCLC) and commonly consists of 1st line therapy with etoposide and platinum (cisplatin or carboplatin), followed by alternative cytotoxic regimens at the time of progression. Only a minority of patients are able to receive 2nd line therapy, and cytotoxics derived from the SCLC paradigm such as topotecan or lurbinectedin have very limited activity. We aimed to evaluate emerging therapeutic options in the 2nd and later lines and survey potential future developments in this space.
RECENT FINDINGS: After a long period of stagnation in treatment options and outcomes, more promising regimens are gradually being utilized in the 2nd line setting including systemic therapy combinations such as FOLFIRI, FOLFOX, modified FOLFIRINOX, CAPTEM, and, more recently, novel checkpoint inhibitors such as nivolumab and ipilimumab. Simultaneously, advances in the understanding of disease biology are helping to refine patient selection and identify commonalities between NEC and their sites of origin which may eventually lead to additional targeted therapy options. While many questions remain, contemporary developments give grounds for optimism that improved outcomes for EP-NEC will soon be within reach.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current oncology reports - 25(2023), 10 vom: 22. Okt., Seite 1127-1139 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Andreatos, Nikolaos [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Genomics |
|---|
| Anmerkungen: |
Date Revised 05.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s11912-023-01438-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361054343 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361054343 | ||
| 003 | DE-627 | ||
| 005 | 20231226084331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11912-023-01438-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM361054343 | ||
| 035 | |a (NLM)37606874 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Andreatos, Nikolaos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a PURPOSE OF REVIEW: Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare, aggressive malignancy that can arise from any organ and frequently presents with distant metastases. Advanced disease has a poor prognosis with median overall survival (OS) rarely exceeding 1 year even with systemic therapy. The management paradigm of advanced/metastatic EP-NEC has been extrapolated from small cell lung cancer (SCLC) and commonly consists of 1st line therapy with etoposide and platinum (cisplatin or carboplatin), followed by alternative cytotoxic regimens at the time of progression. Only a minority of patients are able to receive 2nd line therapy, and cytotoxics derived from the SCLC paradigm such as topotecan or lurbinectedin have very limited activity. We aimed to evaluate emerging therapeutic options in the 2nd and later lines and survey potential future developments in this space | ||
| 520 | |a RECENT FINDINGS: After a long period of stagnation in treatment options and outcomes, more promising regimens are gradually being utilized in the 2nd line setting including systemic therapy combinations such as FOLFIRI, FOLFOX, modified FOLFIRINOX, CAPTEM, and, more recently, novel checkpoint inhibitors such as nivolumab and ipilimumab. Simultaneously, advances in the understanding of disease biology are helping to refine patient selection and identify commonalities between NEC and their sites of origin which may eventually lead to additional targeted therapy options. While many questions remain, contemporary developments give grounds for optimism that improved outcomes for EP-NEC will soon be within reach | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Genomics | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Neuroendocrine carcinoma | |
| 650 | 4 | |a Targeted inhibitors | |
| 700 | 1 | |a McGarrah, Patrick W |e verfasserin |4 aut | |
| 700 | 1 | |a Sonbol, Mohamad Bassam |e verfasserin |4 aut | |
| 700 | 1 | |a Starr, Jason S |e verfasserin |4 aut | |
| 700 | 1 | |a Capdevila, Jaume |e verfasserin |4 aut | |
| 700 | 1 | |a Sorbye, Halfdan |e verfasserin |4 aut | |
| 700 | 1 | |a Halfdanarson, Thorvardur R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current oncology reports |d 1999 |g 25(2023), 10 vom: 22. Okt., Seite 1127-1139 |w (DE-627)NLM110371534 |x 1534-6269 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:10 |g day:22 |g month:10 |g pages:1127-1139 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11912-023-01438-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 10 |b 22 |c 10 |h 1127-1139 | ||